eGFR-creatinine estimates kidney filtration capacity based on serum creatinine levels, measured in mL/min/1.73m². It is the standard marker for staging chronic kidney disease and is essential for safe medication dosing. eGFR-creatinine is directly used to guide clinical decisions about ACE inhibitors, NSAIDs, diuretics, and dozens of other medications whose dosing or use depends on kidney function.
This is a derived biomarker — calculated from directly measured serum creatinine using the CKD-EPI 2021 equation (race-free) or LMREV equation as recommended in Swedish clinical practice, rather than measured directly.
Analyzed in accredited Swedish clinical laboratories (ISO 15189). Used to support clinician-directed evaluation and monitoring. Not a stand-alone diagnosis.
If you are on any medication—particularly blood pressure drugs, diabetes medications, NSAIDs, or anticoagulants—or if you have a family history of kidney disease, hypertension, or diabetes, your kidney function must be monitored. eGFR-creatinine is the standard test that reveals whether your kidneys are filtering waste efficiently.
This test is particularly important as a baseline. Even without symptoms, declining kidney function can be silent for years. Catching decline early allows your clinician to adjust medications and adjust lifestyle factors before irreversible damage occurs.
In Sweden, eGFR-creatinine is part of standard vårdcentral screening, especially for individuals over 50, those on chronic medications, or anyone with metabolic risk factors. It is one of the most frequently ordered tests in clinical medicine because its interpretation has direct consequences for every medication adjustment and every monitoring protocol.
Guides medication safety and dosing. Dozens of medications require dose reduction or avoidance in kidney disease—eGFR-creatinine is the primary variable used to determine safe dosing thresholds for ACE inhibitors, NSAIDs, metformin, antibiotics, and anticoagulants.
Stages chronic kidney disease accurately. CKD is staged G1–G5 based primarily on eGFR-creatinine; knowing your stage determines which specialist referrals, preventive interventions, and monitoring schedules are appropriate.
Identifies silent kidney decline. Many people with declining kidney function have no symptoms until very late stages. Serial eGFR-creatinine measurements reveal the trajectory and allow early intervention.
Flags drug–kidney interactions early. Medications that block tubular creatinine secretion (trimethoprim, cimetidine, cobicistat) raise creatinine without changing true GFR; serial testing and contextual interpretation (e.g., reflex to cystatin-C) can distinguish real decline from drug artifact.
Contextualizes other biomarkers. Many blood results are interpreted differently depending on kidney function (eGFR alters the interpretation of potassium, phosphate, and uric acid, among others).
Predicts long-term health and longevity risk. Low eGFR is a robust independent predictor of cardiovascular mortality, all-cause mortality, and disability, even in the absence of proteinuria.
The filtration story. Your kidneys filter waste from the blood by forcing water and small molecules through the glomerular basement membrane into the tubules, where useful substances (glucose, amino acids, ions) are reabsorbed, and waste (creatinine, urea, excess ions) is concentrated and excreted as urine. Glomerular filtration rate (GFR) is the volume of fluid filtered per minute per unit of body surface area, measured in mL/min/1.73m². It is the single best marker of overall kidney function.
Why creatinine? Creatinine is a small, freely filtered waste product of muscle metabolism. In steady state, the amount filtered per day equals the amount produced by muscles—so serum creatinine concentration mirrors the balance between production (muscle mass, protein intake, meat consumption) and clearance (kidney function). When kidneys fail, creatinine accumulates. Creatinine is measured directly; eGFR is derived from creatinine using mathematical equations that account for age, sex, and race (or race-free variants).
The equations. In Sweden, the CKD-EPI 2021 race-free equation and the LMREV equation are the recommended standards. Both are superior to the older MDRD equation. The CKD-EPI 2021 equation has the form: eGFR = 142 × (Cr/λ)α × (0.9938)age × [1.012 if female], where Cr is creatinine in mg/dL, λ and α are constants that differ by sex and creatinine level. The key advance in 2021 was removal of racial/ethnic coefficients, which had embedded healthcare disparities and lacked scientific justification.
Identifies hidden CKD before symptoms emerge. CKD is asymptomatic until late stages; many people with eGFR of 45–59 (stage G3b) have no idea their kidney function is declining. By the time symptoms appear (fatigue, nausea, fluid retention), renal damage is often irreversible. Serial testing catches the trajectory early.
Reveals medication-kidney mismatches. Many medications are nephrotoxic or renally cleared; using them at full dose in declining kidney function accelerates damage. Conversely, some drugs (trimethoprim, cimetidine) raise creatinine without changing true GFR. Testing reveals these patterns and guides safe prescribing.
Predicts mortality risk independently. Low eGFR is associated with increased cardiovascular mortality, infection risk, and all-cause mortality, even in people without proteinuria or hypertension. This association is causal for some pathways (uremia, mineral dysregulation, inflammation) and correlational for others (shared comorbidities), but the predictive power is robust.
Contextualizes related markers. Potassium, phosphate, and uric acid interpretation depend on kidney function; high potassium in someone with eGFR 20 is an emergency, while the same value in someone with eGFR 80 may be benign. Similarly, anemia in CKD has a different differential diagnosis and urgency than anemia in normal kidney function.
CKD Stage G1 (Normal kidney function): eGFR ≥ 90 mL/min/1.73m². This is the reference range; kidney disease may still be present if albuminuria is elevated, but filtration is preserved.
CKD Stage G2 (Mildly reduced kidney function): eGFR 60–89 mL/min/1.73m². Kidney function is mildly reduced but usually does not require medication dose adjustment. Monitoring for decline and assessment for albuminuria is warranted.
CKD Stage G3a (Mildly to moderately reduced): eGFR 45–59 mL/min/1.73m². Medication review and possible dose adjustments begin here; ACE inhibitors and NSAIDs require caution.
CKD Stage G3b (Moderately to severely reduced): eGFR 30–44 mL/min/1.73m². Most medications require dose reduction; metformin is typically avoided; referral to nephrology is appropriate.
CKD Stage G4 (Severely reduced): eGFR 15–29 mL/min/1.73m². Multiple medication restrictions; nephrology referral is essential; preparation for renal replacement therapy (dialysis or transplant) begins.
CKD Stage G5 (Kidney failure): eGFR < 15 mL/min/1.73m². Renal replacement therapy is required or imminent.
Loovi's proactive approach targets eGFR ≥ 60 as a minimum longevity baseline, with optimization at ≥ 75–80 for individuals without albuminuria. The delta between G2 and G3a (eGFR 60) is where medication review and lifestyle intervention become urgent.
High eGFR (≥ 90 mL/min/1.73m²). Your kidneys are filtering normally for your age. No immediate kidney-based medication restrictions. However, very high eGFR (especially > 120) in older adults or in the absence of prior high baseline can sometimes reflect false elevation due to low muscle mass (elderly, sarcopenic individuals have lower creatinine production, which inflates the calculated eGFR). If your eGFR is unexpectedly high and you are frail or have very low muscle mass, consider reflex testing to cystatin-C for confirmation.
Optimal eGFR (60–89 mL/min/1.73m²). Your kidneys are functioning well. Most medications can be prescribed at standard doses. Annual monitoring is appropriate. If eGFR is slowly declining (falling 5–10 mL/min/1.73m² per year), investigate causes: uncontrolled blood pressure, diabetes, NSAID overuse, or undiagnosed renal disease. Albuminuria status should be assessed by urine albumin-to-creatinine ratio (UACR).
Mildly reduced eGFR (45–59 mL/min/1.73m²). CKD stage G3a–G3b. Many medications require dose reduction or monitoring (NSAIDs, ACE inhibitors, certain antibiotics, metformin). Blood pressure target becomes < 130/80 mmHg. Albuminuria assessment is critical; if present, progression risk is higher. Referral to nephrology is appropriate, especially if decline is rapid (> 5 mL/min/1.73m² per year) or if albuminuria is significant. Nutritional review (protein intake, sodium, phosphate) becomes part of the plan.
Moderately reduced eGFR (30–44 mL/min/1.73m²). CKD stage G4. Medication choices are severely constrained; many common drugs must be avoided or drastically dose-reduced. Nephrology referral is essential. Preparation for renal replacement therapy (dialysis or transplant evaluation) may begin. Mineral and bone metabolism become disordered (calcium, phosphate, parathyroid hormone). Anemia screening (via hemoglobin and iron studies) is part of routine monitoring. Cardiovascular risk is very high.
Severely reduced eGFR (< 15 mL/min/1.73m²). CKD stage G5 (kidney failure). Renal replacement therapy (dialysis or transplant) is required or imminent. Multidisciplinary care involving nephrology, dietetics, and social work is standard. Life expectancy and quality of life depend strongly on adherence to the renal replacement regimen.
Factors that influence eGFR-creatinine results. Serum creatinine is not just a marker of kidney function; it reflects the balance between muscle mass and kidney clearance. Athletes and muscular individuals have higher baseline creatinine and may have eGFR values that appear low despite normal kidney function. Conversely, frail elderly patients, those with sarcopenia, and individuals on low-protein diets have low creatinine production and may have falsely high eGFR. Creatinine also rises transiently after intense exercise, high meat intake (cooked meats are high in creatinine), and dehydration. Certain medications (trimethoprim, cimetidine, cobicistat, dolutegravir) inhibit tubular creatinine secretion and raise serum creatinine without changing true GFR—creating a false impression of kidney decline. This is why serial measurement and contextual interpretation are essential, and why reflex to cystatin-C or averaged eGFR formulas are used in ambiguous cases.
Chronic kidney disease from hypertension or diabetes. Sustained high blood pressure damages glomeruli over decades; persistently elevated blood glucose damages the filtration barrier. These are the two most common causes of CKD globally. Tight blood pressure control (< 130/80 mmHg) and good glycemic control (HbA1c < 53 mmol/mol / < 7%) slow or halt progression.
Glomerulonephritis and autoimmune renal disease. Lupus, IgA nephropathy, membranoproliferative glomerulonephritis, and other conditions cause inflammation in the glomeruli, leading to proteinuria and declining filtration. These are often asymptomatic until advanced.
Nephrotoxic medications and substances. NSAIDs, ACE inhibitors in certain settings (dehydration, bilateral renal artery stenosis), chemotherapy agents (cisplatin), some antibiotics (aminoglycosides, amphotericin), and contrast dye can all cause acute or chronic kidney injury.
Obstruction and structural disease. Kidney stones, tumors, benign prostatic hyperplasia, and other conditions that obstruct urine flow can impair kidney function. Most are reversible if diagnosed early.
Age-related decline. GFR naturally declines ~0.5–1 mL/min/1.73m² per year after age 40 in most adults, even without disease. This is called senescent renal aging. It is slower in people with excellent blood pressure and metabolic control, but it occurs in everyone to some degree.
Blood pressure control. Sustained hypertension is the single most modifiable driver of CKD progression. Tight blood pressure control (target < 130/80 mmHg) slows glomerular damage. Both ACE inhibitors and angiotensin-receptor blockers have additional renoprotective effects beyond their blood pressure lowering—they reduce glomerular capillary pressure and proteinuria.
Glycemic control (if diabetic). Persistent hyperglycemia drives glomerular injury through glycation and inflammation. Metformin also has mild renoprotective effects, though it must be used cautiously once eGFR falls below 45 mL/min/1.73m². GLP-1 receptor agonists (semaglutide, liraglutide) have shown cardiovascular and renal protection in large trials and are increasingly recommended in diabetic CKD.
NSAID avoidance or minimization. NSAIDs reduce renal perfusion and can cause acute kidney injury, especially in dehydrated states or in combination with ACE inhibitors. In CKD, NSAIDs accelerate progression. Acetaminophen is a safer analgesic; topical NSAIDs are alternatives for localized pain.
Adequate hydration and sodium moderation. Dehydration triggers acute kidney injury; chronic dehydration accelerates senescent decline. Conversely, high sodium intake raises blood pressure and increases proteinuria. Sodium restriction (target < 5 g/day / < 2300 mg/day) is part of CKD management.
Weight management and physical activity. Obesity is associated with glomerular hyperfiltration and progressive CKD. Regular aerobic activity and resistance training improve blood pressure, insulin sensitivity, and overall metabolic health, which all protect kidney function. Exercise does not directly raise GFR, but it prevents the metabolic derangements that cause decline.
Protein intake optimization. The role of protein in CKD is nuanced. Very high protein intake (especially from animal sources) increases glomerular hyperfiltration and can accelerate decline. However, protein restriction below ~0.8 g/kg/day risks malnutrition and muscle loss. The current consensus is modest protein intake (0.8–1.0 g/kg/day) with emphasis on plant-based sources where possible.
Ultimately, the right combination of interventions depends on your eGFR level, albuminuria status, comorbidities (diabetes, cardiovascular disease), and the speed of decline—all factors a Loovi longevity doctor maps out in consultation. The lever that works for one person may not be the highest priority for another.
eGFR-creatinine has inherent limitations. Muscle mass, diet, medications, and hydration status all affect creatinine independent of true kidney function. A frail 80-year-old with eGFR 75 and a muscular 40-year-old athlete with eGFR 95 are in very different clinical situations, but creatinine-based eGFR alone cannot distinguish them.
This is why cystatin-C, a cysteine protease inhibitor filtered freely by the glomerulus and not affected by muscle mass or diet, is increasingly used as a complementary marker. Cystatin-C-based eGFR and averaged eGFR (the mean of creatinine-based and cystatin-C-based estimates) provide a more robust picture in ambiguous cases. Albuminuria (measured as urine albumin-to-creatinine ratio) is equally critical—it reflects glomerular damage independent of GFR and is a powerful independent predictor of progression and cardiovascular risk. Together, eGFR, cystatin-C, and albuminuria form the Loovi kidney function panel.
A Loovi membership tracks your full renal biomarker profile—eGFR-creatinine, cystatin-C, eGFR-cystatin-C, and albuminuria—year over year. You also get unrushed consultations with a longevity doctor who interprets these markers in the context of your blood pressure, metabolic health, medications, and family history. This contextual, multidimensional approach is how silent CKD is caught early and how progression is slowed or halted.
This discordance typically reflects high muscle mass or recent meat intake inflating your creatinine. Young athletes, bodybuilders, and people who have eaten large amounts of cooked meat in the 24 hours before testing often show this pattern. Cystatin-C is not affected by muscle mass or diet, so cystatin-C-based eGFR is more accurate in this scenario. This is not a sign of kidney disease; it is an example of why reflex to cystatin-C is useful when creatinine-based eGFR seems discordant with clinical context.
Yes. Trimethoprim, cimetidine, cobicistat, and dolutegravir inhibit tubular creatinine secretion in the kidney, raising serum creatinine without changing true GFR. If you start one of these drugs and your eGFR appears to drop 10–20 mL/min/1.73m² within days or weeks, and then stabilizes, this is likely a drug effect, not kidney damage. However, you cannot distinguish this purely from serum creatinine; your clinician will monitor trends and may reflex to cystatin-C for confirmation. Do not stop the medication based on eGFR alone—discuss with your doctor.
Both. Loovi tracks both. Creatinine-based eGFR is the standard used for medication dosing and CKD staging; cystatin-C-based eGFR is more accurate in individuals with extreme muscle mass or diet variability. The averaged eGFR (mean of both) is the most robust single estimate. Do not choose one over the other; clinicians use both to triangulate true kidney function.
eGFR-creatinine is covered by standard vårdcentral testing and is part of routine health checks, especially for anyone over 50 or on chronic medications. It is one of the most frequently ordered tests in Swedish primary care. Cystatin-C and albumin-to-creatinine ratio may require private longevity testing depending on your clinic. Loovi includes all three as part of the annual biomarker panel.
In healthy people without CKD, eGFR declines ~0.5–1 mL/min/1.73m² per year due to age. In someone with diabetes or hypertension, decline can accelerate to 3–5 mL/min/1.73m² per year without intervention. Rapid decline (> 5 mL/min/1.73m² per year) warrants urgent investigation for secondary causes—uncontrolled blood pressure, new medication, obstruction, or acute glomerulonephritis. The biology responds to blood pressure control and metabolic optimization over months to years; there is no quick fix, but sustained intervention can slow or halt decline.
Yes. Intense exercise, particularly resistance training and endurance events, can transiently raise serum creatinine for 24–48 hours due to muscle damage and increased creatinine release. If you exercise heavily the day before or the morning of testing, your eGFR may appear falsely low. For accurate baseline measurement, avoid intense exercise for 48 hours before blood draw and ensure you are well-hydrated.
Stable low eGFR, even over years, is not normal kidney function, but it is not progressive CKD if the rate of decline is zero. Your risk of complications (electrolyte disorders, anemia, bone disease, cardiovascular events) is higher than someone with eGFR 70, and you require closer monitoring and medication review. However, you may not need urgent nephrology referral if your eGFR is stable, albuminuria is absent or minimal, and blood pressure is controlled. Your Loovi doctor will discuss the individual risk–benefit calculus and monitoring schedule.
Once glomeruli are permanently scarred, that damage cannot be reversed. However, eGFR decline can be halted or slowed. Tight blood pressure and glucose control, NSAID avoidance, and optimal medication selection (ACE inhibitors, GLP-1 agonists, SGLT2 inhibitors in diabetes) can prevent further loss of function and extend the time before renal replacement therapy is needed. Early detection via testing is why eGFR-creatinine matters—interventions work best before irreversible scarring occurs.
